NCT00429923已完成3 期
A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 219
- 试验地点
- 1
- 主要终点
- Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo).
研究概览
简要总结
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unilateral ocular surgery in the day prior to study enrollment.
- •Anterior chamber cell grade ≥ "2" on the day after surgery (Day 1).
- •Aged 2 years or older on the day of consent.
- •Negative urine pregnancy test on Day 1 for postmenarchal subjects; negative urine pregnancy test for premenarchal subjects at the investigator's discretion.
- •Provide signed written consent prior to entering the study or signed written consent from parent or legal guardian if subject is a minor and signed assent from minor subject, if appropriate.
- •Presurgical
排除标准
- •Systemic administration of any corticosteroid in the 2 weeks prior to study enrollment.
- •Periocular injection in the study eye of any corticosteroid solution within 4 weeks prior to instillation of the study drug, or of any corticosteroid depot within 2 months prior to instillation of the study drug.
- •Instillation of any topical ocular corticosteroid or NSAID within 24 hours prior to instillation of the study drug or during the course of the study, with the exception of presurgical administration of a topical NSAID to prevent miosis.
- •Any history of glaucoma or ocular hypertension in the study eye.
- •History or presence of endogenous uveitis.
- •Any current corneal abrasion or ulceration.
- •Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease.
- •Allergy to similar drugs, such as other corticosteroids.
- •History of steroid-related IOP increase.
- •Scheduled surgery on the contralateral eye during the treatment period.
- •Unwilling to discontinue use of contact lenses during the study period.
- •Pregnancy or lactation.
- •Participation in any study of an investigational topical or systemic new drug or device within 30 days prior to screening, or at any time during the study.
- •Prior participation in the study described in this protocol.
- •Unable or unwilling to give signed informed consent prior to participation in any study related procedures.
- •Postsurgical Exclusion Criteria:
- •Ocular hemorrhage which interferes with evaluation of postsurgery inflammation.
- •Injection of gas into the vitreous body during surgery.
- •Presence of IOP ≥24 mm Hg on Day 1 after surgery.
研究组 & 干预措施
Difluprednate 0.05% BID
Experimental
Difluprednate 0.05% 1 drop BID for 14 days.
干预措施: Difluprednate (Drug)
Difluprednate 0.05% QID
Experimental
Difluprednate 0.05% 1 drop QID for 14 days.
干预措施: Difluprednate (Drug)
Placebo
Placebo Comparator
Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
干预措施: Placebo (Drug)
结局指标
主要结局
Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo).
时间窗: Day 8 (QID)
Measured on a 0 to 4 scale: "0" is ≤ 1 cell; "1" is 2-10 cells; "2" is 11-20 cells; "3" is 21-50 cells; "4" is \> 50 cells.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)InflammationNCT00430092Sirion Therapeutics, Inc.219
已完成
3 期
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior UveitisEndogenous Anterior UveitisNCT01201798Alcon Research111
已完成
3 期
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)InflammationNCT00616070Sirion Therapeutics, Inc.120
已完成
3 期
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)InflammationNCT00616993Sirion Therapeutics, Inc.120
已完成
3 期
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)Chronic Hepatitis BHepatitis B, ChronicNCT05630807GlaxoSmithKline981